The Impact of Lipoprotein Apheresis on Changes in Biochemical Enzymes: A Systematic Review and Meta‐Analysis
Journal of Clinical Apheresis · 2026
DOI: 10.1002/jca.70100 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical Apheresis, 2026. Verfasst von Alireza Hatami und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Blood Transfusion, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Hauptthemen laut MEDLINE: Blood Component Removal, Lipoproteins, Dyslipidemias, Enzymes. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Lipoprotein apheresis (LA) is an established therapy for severe, drug‐refractory dyslipidemias. Nevertheless, clinicians often monitor hepatic and muscle enzymes during treatment because transient biochemical shifts can be misinterpreted as injury. In this study, we synthesize the evidence on how repeated apheresis sessions affect circulating enzymes. We systematically searched PubMed, Scopus and Web of Science from inception to August 2025 for observational human studies reporting pre‐ and post‐apheresis values (mean and SD) for aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma‐glutamyl transferase (GGT), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Effects were expressed as weighted mean differences (WMD, IU/L). Of 267 records screened, 9 articles (published 1998–2006) met eligibility for quantitative synthesis, yielding 9 ALT, 8 AST, 7 ALP, 6 GGT, 9 LDH and 6 CPK study estimates. Pooled analyses showed significant decreases in AST (WMD = −0.87; 95% CI: −1.51 to −0.23; p = 0.007), ALP (WMD = −6.28; CI: −11.75to −0.80; p = 0.02), LDH (WMD = −11.12; CI: −17.01 to −5.24; p = 0.001) and CPK (WMD = −6.91; CI: −13.06 to −0.75; p = 0.02). However, levels of ALT (WMD = −0.78; CI: −2.10 to 0.53; p = 0.29) and GGT (WMD = −2.64; CI: −8.71 to 3.44; p = 0.39) were unchanged. Across repeated‐session studies, LA does not elevate hepatic or muscle injury markers and is associated with modest reductions in AST, ALP, LDH, and CPK. These findings support the biochemical safety profile of apheresis and suggest that routine enzyme monitoring should be interpreted in context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Blood Transfusion, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Surgery, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
- Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Laboratory Sciences and Hematology, School of Allied Medical Science, North Khorasan University of Medical Sciences, Bojnurd, Iran.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
ORCID-Profile: Amirhossein Sahebkar
Zitieren
APA
Hatami, A., Eslami, M., Aslani, S., Jamialahmadi, T., Razi, B., & Sahebkar, A. (2026). The Impact of Lipoprotein Apheresis on Changes in Biochemical Enzymes: A Systematic Review and Meta‐Analysis. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70100
Vancouver
Hatami A, Eslami M, Aslani S, Jamialahmadi T, Razi B, Sahebkar A. The Impact of Lipoprotein Apheresis on Changes in Biochemical Enzymes: A Systematic Review and Meta‐Analysis. Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70100
BibTeX
@article{Hatami2026,
author = {Hatami, Alireza and Eslami, Masoud and Aslani, Saeed and Jamialahmadi, Tannaz and Razi, Bahman and Sahebkar, Amirhossein},
title = {The Impact of Lipoprotein Apheresis on Changes in Biochemical Enzymes: A Systematic Review and Meta‐Analysis},
journal = {Journal of Clinical Apheresis},
year = {2026},
doi = {10.1002/jca.70100}
}
EUVIMED